

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

# **Patient Group Direction (PGD)**

For the administration or supply of

# **Hydroxocobalamin injection 1000 micrograms**

By registered health care professionals for

**Vitamin B12 deficiency** 

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

### **PGD NUMBER 96**

### 1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021

Reference number: 96 Valid from: 03/2020 Review date: 03/2023

Version: 1 Page 1 of 6

### 2. Medicines practice guideline 2: Patient group directions

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care <u>PGD</u> website FAQs

### 3. PGD development

Refer to the <u>NICE PGD competency framework for people developing PGDs</u>

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

### 4. PGD authorisation

Refer to the <u>NICE PGD competency framework for people authorising PGDs</u>

Job Title	Name	Signature	Date
Medical Director			
Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)			

Reference number: 96 Valid from: 03/2020 Review date: 03/2023

# 5. PGD adoption by the provider

Refer to the <u>NICE PGD competency framework for people authorising PGDs</u>

Job title and organisation	Signature	Date	Applicable or not applicable to area

# 6. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the <u>NICE PGD competency framework for health professionals using PGDs</u>

	Requirements of registered Healthcare professionals working under the PGD	
Qualifications and professional registration	Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are	
	permitted staff groups outlined within the current PGD policy	
	Pharmacists must be practising in Manx Care authorised	
	premises i.e. contracted pharmacy premises	
Initial training	<ul> <li>Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and</li> </ul>	
	exclusion criteria	
	Training which enables the practitioner to make a clinical	
	assessment to establish the need for the medication covered by	
	this PGD	
	Local training in the use of PGDs	
Competency	Staff will be assessed on their knowledge of drugs and clinical	
assessment	assessment as part the competency framework for registered health	
	professionals using PGDs	
Ongoing training and	The registered health care professionals should make sure they are	
competency	aware of any changes to the recommendations for this medication;	
	it is the responsibility of the registered health care professionals to	
	keep up to date with continuing professional development. PGD	
	updates will be held every two years	

Reference number: 96 Valid from: 03/2020 Review date: 03/2023

### 7. Clinical Conditions

Clinical condition or	Vitamin B12 deficiency
	Vitamin B12 deficiency
situation to which this	
PGD applies	
Inclusion criteria	Patients over the age of 16 years
	Addisonian pernicious anaemia
	Tobacco amblyopia (poor sight caused by toxins such as tobacco)
	Leber's atrophy (Degeneration of the optic nerve resulting in
	loss of central vision)
	Treatment/prevention of other macrocytic anaemias due to
	deficiency in vitamin B12
	Vitamin B12 should be given prophylactically after total
	gastrectomy or total ileal resection (or after partial gastrectomy
	if vitamin B12 absorption test shows vitamin B12 malabsorption)
Exclusion criteria	Patients under the age of 16 years
	Diagnosis not fully established
	<ul> <li>Previous history of sensitivity to vitamin B12 or are allergic to</li> </ul>
	any of the ingredients
	<ul> <li>Should not be used to treat certain types of anaemia during</li> </ul>
	pregnancy
Cautions (including any	Should not be given before diagnosis fully established
relevant action to be	and the second s
taken)	
Arrangements for referral	Patient should be referred to a more experienced clinical
for medical advice	practitioner for further assessment
Action to be taken if	Patient should be referred to a more experienced clinical
patient excluded	practitioner for further assessment
Action to be taken if	A verbal explanation should be given to the patient on: the need
patient declines	for the medication and any possible effects or potential risks
treatment	which may occur as a result of refusing treatment
. Cathlette	<ul> <li>This information must be documented in the patients' health</li> </ul>
	records
	<ul> <li>Any patient who declines care must have demonstrated capacity to do so</li> </ul>
	Where appropriate care should be escalated

### 8. Details of the medicine

Name, form and strength	Hydroxocobalamin injection 1000 micrograms
of medicine	
Legal category	Prescription only medicine (POM)
Indicate any off-label use	None
(if relevant)	
Route/method of	Intramuscularly
administration	

Reference number: 96 Valid from: 03/2020 Review date: 03/2023

Dose and frequency	Initial dose: 1000mcg given on alternate days (5 doses) over a two week period		
	Maintenance dose: 1000mcg every three months if vitamin B12 levels are insufficient/Intrinsic factor level is unacceptable		
Quantity to be administered and/or supplied	As per dose		
Maximum or minimum treatment period	One episode of care based on blood levels		
Storage	Room temperature		
Adverse effects	Diarrhoea	• Chills	
	<ul> <li>Dizziness</li> </ul>	<ul> <li>Drug fever</li> </ul>	
	<ul> <li>Headache</li> </ul>	<ul> <li>Hypokalaemia</li> </ul>	
	Hot flush	<ul> <li>Malaise</li> </ul>	
	<ul> <li>Nausea</li> </ul>	<ul><li>Pain</li></ul>	
	<ul> <li>Skin reactions</li> </ul>	<ul> <li>Thrombocytosis</li> </ul>	
	<ul> <li>Urine discolouration</li> </ul>	<ul><li>Tremor</li></ul>	
	<ul> <li>Arrhythmia</li> </ul>	<ul><li>Vomiting</li></ul>	
Records to be kept	The administration of any medication given under a PGD must be		
	recorded within the patient's	medical records	

### 9. Patient information

Verbal/Written information to be given to patient or carer	<ul> <li>Verbal information must be given to patients and or carers for all medication being administered under a PGD</li> <li>Where medication is being supplied under a PGD, written patient information leaflet must also be supplied</li> <li>A patient information leaflet is available on request</li> </ul>
Follow-up advice to be	If symptoms do not improve or worsen or you become unwell, seek
given to patient or carer	medical advice immediately

# 10. Appendix A

# References

- 1. British National Formulary (BNF) available online: <a href="https://bnf.nice.org.uk">https://bnf.nice.org.uk</a>
- 2. Nursing and Midwifery (2018) "The code" available online: https://www.nmc.org.uk
- 3. Current Health Care Professions Council standards of practice
- 4. General Pharmaceutical Council standards
- 5. The General Optical Council
- 6. Electronic medicines compendium available online: <a href="https://www.medicines.org.uk">https://www.medicines.org.uk</a>

Reference number: 96 Valid from: 03/2020 Review date: 03/2023

Version: 1 Page 5 of 6

# 11. Appendix B

# Health professionals agreed to practice

- Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor
- A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves

Reference number: 96 Valid from: 03/2020 Review date: 03/2023